1

Hong Kong-listed companies have repurchased far more of their own shares this year while spending less than they did last year. The difference reflects prices rather than weaker demand: shares became cheaper, allowing the same amount of cash to buy more stock. The overall picture is also far more concentrated than the headline figure suggests.

More Shares, Less Money: The Math Behind the Headline

On Sept. 4, the Shanghai Securities News, citing market statistics, reported that buybacks by Hong Kong-listed companies had exceeded HK$100 billion as of Sept. 3. The total reached HK$109.413 billion (about US$14 billion) across 8.24 billion shares. The number of shares repurchased rose 55.4% from a year earlier, while the Hang Seng Index was down 1.63% year to date over the same period.

A second figure in the report is easier to overlook: the HK$109.413 billion total was lower than the comparable figure last year. Working backward from the published data, companies repurchased about 5.3 billion shares during the year-earlier period while spending more than they did on this year's 8.24 billion shares. That indicates average purchase prices were generally lower than a year ago. The divergence suggests companies are buying more aggressively during a period of lower valuations, rather than suddenly having more cash available for shareholder returns.

Five Companies Account for More Than Half the Total

The buying is also concentrated. According to the Shanghai Securities News tally, the five largest buyers by value as of Sept. 3 were Tencent Holdings, at HK$29.432 billion; AIA Group, HK$13.635 billion; Xiaomi Group-W, HK$11.814 billion; China Hongqiao, HK$5.287 billion; and ZTO Express-W, HK$3.269 billion. Together, they accounted for HK$63.437 billion, or about 58% of total buyback value. Tencent alone represented nearly 27%. The group spans information technology, financial services, consumer discretionary, logistics and cyclical industries.

The phrase "HK$100 billion" suggests a market-wide trend. In practice, however, it largely reflects the financial decisions of a small number of cash-rich companies — a distinction that shapes the rest of the story.

Tencent Is Deliberately Slowing Its Buybacks to Fund AI

Tencent's slowdown is a key reason this year's total trails last year's. According to a Sept. 2 report compiled by Cailian Press, Tencent repurchased HK$112 billion in 2024, the largest amount in the Hong Kong market, before the figure fell to HK$80 billion in 2025, a decline of about 29%. During the first eight months of 2026, Tencent bought back about HK$29.1 billion in shares.

Its daily buying has dropped sharply, from more than 4 million shares at points during the 2024 market slump to 226,000 shares worth about HK$100 million on Sept. 1. Cailian Press's day-by-day tally of HKEX filings showed daily buybacks running at about HK$300 million in mid-to-late August before falling to roughly HK$100 million from September.

Tencent's management said, as reported by Cailian Press in March 2026, that the company would significantly reduce share repurchases and redirect funds towards AI. It added that 2025 capital expenditure of 79.2 billion yuan (about US$11 billion), up 3% year on year, was already insufficient to meet rising computing costs. All figures above come from media tallies and paraphrased company statements. Specific amounts should be checked against transaction-by-transaction filings on HKEX's HKEXnews disclosure platform.

That is what makes the HK$100 billion figure counterintuitive: the single biggest buyer is deliberately slowing its purchases and shifting cash from shareholder returns towards computing capacity. Buybacks by other companies are generally measured in the hundreds of millions of Hong Kong dollars — not enough to offset the gap created by Tencent's pullback.

Alibaba's Placement Shows Two Different Kinds of Spending

Alibaba offered the clearest example of a related but distinct trade-off. On Aug. 23, the company announced a placing of 710 million new shares at HK$112.70 each, raising about HK$80 billion for AI infrastructure. It confirmed completion of the placing on Aug. 26. Alibaba's Hong Kong-listed shares fell sharply, declining more than 8% intraday on Aug. 24, while its US-listed shares were down about 4% in premarket trading.

Company executives responded by buying shares personally. According to the Shanghai Securities News, founder Jack Ma had accumulated more than HK$600 million in purchases by Aug. 25, while Chairman Joe Tsai and Chief Executive Officer Eddie Wu bought about HK$200 million worth of shares between them on Aug. 24-25. At Kingsoft Corp., Chairman Lei Jun made repeated purchases from Aug. 24 to 27, increasing his stake to 27.41%.

Wen Jie, a director of the Hong Kong Society of Financial Analysts, told reporters that pairing a placing with executive buying signals aligned interests. Management's voluntary decision to increase its holdings also suggests that executives' assessment of the company's value is not dependent on short-term price movements.

The two figures should not be treated as a single story. Alibaba is raising roughly HK$80 billion from the market for AI capital spending, while individuals are spending about HK$800 million to address concerns over dilution. The first is capital expenditure; the second is a signal. Treating Alibaba's stake increases alone as the main event would obscure where the larger amount of money is actually going.

Elsewhere, buying has been smaller and more fragmented. So far this year, executives or major shareholders at Sino Biopharmaceutical, Alisyn Biomedical-B, CStone Pharmaceuticals-B, Antengene-B and Kintor Pharmaceutical-B have increased their holdings, although none of the amounts was disclosed.

The Hang Seng Healthcare Index closed at 3,831.96 on Sept. 3, still down more than 50% from its 2021 peak. Founder Securities said in a research note that Chinese innovative-drug makers had entered an earnings cycle driven by overseas licensing revenue. Data from the National Medical Products Administration showed licensing deals worth more than US$60 billion in the first three months of 2026 alone, nearly half the total for all of 2025.

In the property supply chain, Zuo Manlun, administrative president of China Lesso, bought 43.9091 million shares for about HK$166 million on July 8. Cen Zhiyong, an analyst at Wutong Research Institute, said the stock had fallen into a historically low range while the company's overseas business was expanding more quickly, prompting management to signal confidence through share purchases.

Carmakers have also joined in. Li Auto announced a US$1 billion buyback programme in March, valid through March 2027. Geely Automobile has completed more than HK$1.88 billion of a HK$2.3 billion programme announced last October, while MINIEYE and Great Wall Motor have each repurchased more than HK$100 million worth of shares.

Zhang Xiang, a researcher at the Automotive Industry Innovation Research Center of North China University of Technology, told reporters that automakers' competitive focus was shifting from capacity expansion and price wars towards shareholder returns and market-capitalisation management.

Two figures should be kept separate: "up to HK$X" is a programme ceiling, while "HK$X already repurchased" refers to money actually spent. China Resources Beverage's HK$530 million buyback plan and Weilong Delicious's HK$200 million allocation are ceilings. Mengniu Dairy's HK$143 million, covering 8.61 million shares through Sept. 2, is money already spent. Confusing the two can make a company's actual buying appear larger than it is.

What to Watch Next

Four developments will show whether this shift is temporary or structural. First, whether HKEXnews filings begin specifying that repurchased shares will be cancelled, rather than allocated to employee share schemes. Second, whether Tencent's daily buyback value rises above HK$300 million again or continues moving towards HK$100 million. Third, how much of the HK$80 billion raised through Alibaba's placing is converted into disclosed AI capital spending in the coming quarters. Fourth, whether the Hang Seng Healthcare Index can recover from its drawdown of more than 50% from 2021 levels, and whether biotech companies begin disclosing the size of executive stake increases rather than leaving them unquantified.

The HK$100 billion figure is worth remembering not because it crossed a threshold, but because of what lies beneath it: companies are willing to buy their own shares at lower prices, but are not willing to spend more.

Risk disclosure: Data in this article are drawn from reports by the Shanghai Securities News and Cailian Press. The original tallies do not specify the underlying database or measurement basis. For details of individual buybacks and stake increases, refer to announcements on HKEX's HKEXnews disclosure platform. This article compiles public information and

Originally published on IBTimes Hong Kong